Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NOTE’s Interim Report January–June 2018

Financial performance April–June  • Sales increased by 14% to SEK 350.5 (308.4) million.• Operating profit increased to SEK 23.5 (20.3) million.• Operating margin expanded by 0.1 percentage points to 6.7% (6.6%).• Profit after financial items rose to SEK 21.7 (19.3) million.• Profit after tax increased to SEK 17.0 (11.6) million, corresponding to SEK 0.59 (0.40) per share.• Cash flow after investments was SEK -17.9 (1.3) million, or SEK -0.62 (0.05) per share. Financial performance January–June• Sales increased by 12% to SEK 658.5 (585.5) million.• Operating profit

Enzymatica AB: Court ruling put restrictions on marketing of Enzymatica's cold spray in Germany

Press release July 16, 2018 Court ruling put restrictions on marketing of Enzymatica's cold spray in Germany A decision in the regional court of Frankfurt has put restrictions on the marketing of the mouth spray ViruProtect® in Germany. Enzymatica's ColdZyme® Mouth Spray is sold under the brand name ViruProtect in Germany, Belgium and Austria. The reasons for the court decision - as they are known after the oral hearing - seem to be the strict requirements on the design of clinical studies under German jurisdiction. Enzymatica's distributor in Germany, STADA Arzneimittel, and

Insplorion reaches collaboration agreement with Littelfuse for battery sensor technology

Insplorion AB announced today that it has signed a collaboration agreement with Littelfuse, Inc. for Insplorion’s proprietary NanoPlasmonic Sensing (NPS) battery sensor technology. The aim is that the collaboration leads to improved market activities and technical development needed to accelerate the advancement of this innovative technology into the automotive market."We are excited to take this step with Littelfuse, which we hope will help in bringing our NPS battery sensor technology to the market,” said Patrik Dahlqvist, Insplorion CEO. “We see Littelfuse as a good collaboration partner

Natural stone catches the eye

Facing stones and mosaics made of natural materials are becoming increasingly popular, including in Finland. Kiilto provides reliable fixing solutions for Aitokivi  products.For centuries, natural stone facing has been used to enliven both exterior and interior surfaces in many countries. In Finland, however, the use of facing stone for indoor applications, for example in saunas, is still relatively novel. According to Suomen Aitokivi Oy Marketing Director Viivi Vuorio, natural stone is now making a breakthrough also in Finnish houses. “Natural stone fits in

Camurus announces PDUFA date for CAM2038 for the treatment of opioid use disorder

Lund, Sweden – 16 July 2018 — Camurus (NASDAQ STO: CAMX) announced today that the US Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2018 for its investigational weekly and monthly buprenorphine depots, CAM2038, for the treatment of adults with opioid use disorder (OUD).  The FDA considers the resubmission of the New Drug Application (NDA) by Camurus’ US partner Braeburn a complete response to the January 19, 2018, action letter. “We are pleased that the FDA has assigned a target action date for a US approval decision for

Bactiguard enters new partnership for Germany

Bactiguard has entered a new partnership with Asid Bonz GmbH (Asid Bonz) through an exclusive distribution agreement for Germany, including all products in Bactiguard's portfolio.“Asid Bonz is an experienced, well respected and professionally managed partner that shares our ambitions to grow in the German market by offering premium products and services to the healthcare sector. By teaming up with Asid Bonz’s well connected team, we are confident that we will see a rapid roll-out of our product portfolio and increased market penetration across Germany”, says Christian Kinch, CEO. “We

INTERIM REPORT JANUARY-JUNE 2018

During the second quarter, the implementation of the strategic plan continued at a high pace. We have so far this year opened twelve new Byggmax stores, ten Byggmax Garden departments, and continued to develop our ecommercebusiness. The initiatives to transform Skånska Byggvaror are executed according to plan. The initiatives have created positive effects. The new stores have been well received and contribute significantly positively to Byggmax sales growth by the end of the quarter. We can now also conclude that the two growthinitiatives launched during summer 2017, that is a smaller

AKERBP: Evy Glørstad-Clark appointed SVP Exploration of Aker BP

Evy Glørstad-Clark has been appointed SVP Exploration of Aker BP, and will be part of the Executive Management Team. She currently holds a position as Asset Development Manager for NOAKA, and has been with the company since 2011. She holds a PhD in Petroleum geology/ sedimentology. She will commence in her new role on August 1st 2018. Gro Gunleiksrud Haatvedt will take a position as Head of Exploration at Neptune Energy in London. Karl Johnny Hersvik, CEO of Aker BP states: “Evy has a strong managerial and professional track record. I am looking forward to welcoming her to my

Double Bond Pharmaceutical has been granted Eurostars funding for development a new product for treatment of pneumonia

A consortium consisted of Double Bond Pharmaceutical together with Karolinska Institute and international partnering SMEs from France has been granted a Eurostars funding. The project has a work name Belopenem and will be focused on developing a novel antibiotic formulation that targets the lung after a simple i.v. injection. The aim of the project is thus to develop a novel and more effective treatment of pneumonia based on Double Bond Pharmaceutical's drug-delivery technology BeloGal®. The project will be conducted for 2 years with the start in November 2018 and result in a fully

Invitation to Kindred Group’s financial presentation

Kindred Group plc will publish its Interim report for the second quarter 2018 on Wednesday 25 July 2018 at 07.30 (CEST). In connection with this, Kindred Group’s CEO Henrik Tjärnström will host a presentation in English at FinancialHearings, Tändstickspalatset, Västra Trädgårdsgatan 15 in Stockholm at 09.00 (CEST). Please go to www.financialhearings.com to sign in, in advance. The presentation is also web casted live on www.kindredgroup.com. For those who would like to participate in the telephone conference in connection with the presentation, the telephone number is UK: +44

Ericsson, Telstra and Intel achieve first end-to-end multi-vendor 5G commercial network data call over licenced 3.5GHz spectrum

Ericsson (NASDAQ: ERIC), Telstra and Intel have successfully completed the first end-to-end 5G non-standalone (NSA) 3GPP data call on a commercial mobile network at Telstra’s 5G Innovation Centre on the Gold Coast Australia in a multivendor setup. With this achievement, the companies have taken 5G out of the lab and into a real-world mobile network environment.The call was the first of its kind over 3.5GHz spectrum, bringing together the core components from multiple companies required for a real commercial 5G network call. It included Telstra’s 5G NSA commercial network, licenced 3.5GHz

IRRAS Receives FDA Clearance for IRRAflow® in the US

IRRAflow is a transformative medical device that combines controlled irrigation with ongoing fluid drainage for the treatment of patients with intracranial bleeding Plans to launch IRRAflow in the US underwayStockholm, Sweden, July 16, 2018 – IRRAS AB (NASDAQ Stockholm: IRRAS), a commercial-stage medical technology company focused on developing and commercializing transformative treatments to manage intracranial fluids, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for IRRAflow, its integrated, closed medical device system that enables

Sustained strong result for the second quarter

Södra reported sustained strong operating profit of SEK 1,318 million (461) for the second quarter, the best quarterly result ever. The market trend was positive for all of Södra’s product categories and completed investments, efficiency improvements and restructuring are reflected in the result.“The strong result is mainly due to the favourable global economy, with high demand and a positive price trend for our products in both market pulp and the sawn timber area. We are also seeing the positive effects of our expansion investments, with higher production volumes at our pulp mills,” said

Stora Enso shares converted

STORA ENSO OYJ STOCK EXCHANGE RELEASE 16 July 2018 at 9.00 EESTDuring the 1–29 June 2018 conversion period there was one conversion and a total of 13 070 A shares were converted into R shares. The shares were recorded in the Finnish trade register today, 16 July 2018, and trading in the new R shares will start on 17 July 2018.Breakdown of shares after conversion: A shares  176 327 172R shares  612 292 815Total  788 619 987 Each A share and each ten R shares carry one vote. The total amount of votes after the conversion is at least 237 556 453.For further information,

Handelsbanken’s interim report for January-June 2018 will be presented on July 18

Handelsbanken will present its results for January­‑June 2018 in Stockholm on July 18, 2018, at 8:00 a.m. CET, at a meeting with the media and analysts. The interim report for January‑June 2018 will be published at 6:30 a.m. CET, on July 18, 2018. A telephone conference will be held at 10:30 a.m. CET (4:30 a.m. EST), when Rolf Marquardt, CFO, will present and comment on the results. There will also be time for questions from the participants. UK number: +44 203–364 5374Swedish number: +46 8–505 564 74US number: +1 855–753 2230 Instructions1.     Dial +xx xxx xx 10 minutes

SBB, Interim Report January – June 2018: Significant increase in net operating income, Earnings per share SEK 0.67

SAMHÄLLSBYGGNADSBOLAGET I NORDEN AB (PUBL): THE FIRST HALF-YEAR IN BRIEF · Rental income increased to SEK 800 million (585). · Net operating income increased to SEK 505 million (357). · Cash flow from operations before changes in working capital amounted to SEK 155 million (132). · Profit before tax amounted to SEK 687 million (2,140), of which: · Income from property management totalled SEK 182 million (138). After adjustment for one-off effects, the management result totalled SEK 243 million. · Unrealised value changes on properties excluding building rights

Tradedoubler Interim Report January - June 2018

The second quarter April - June 2018 · Net sales amounted to SEK 283 M (284). Net sales adjusted for change related items were SEK 283 M (284), which was a decrease of 1%. · Gross profit adjusted for change related items was SEK 66 M (62), an increase of 6% or 0% adjusted for changes in exchange rates. Gross margin adjusted for change related items was 23.2% (21.9). · Operating costs excluding depreciation and change related items were SEK 58 M (59), a decrease of 2%. · EBITDA amounted to SEK 6 M (-1). Adjusted for change related items, EBITDA was SEK 8 M (3). · Capitalised

THE MARKETING GROUP PLC: TRUTH LAUNCHES ICO PRE-SALE FOR BLOCKCHAIN-BASED DATA MARKETPLACE

Truth Media Ltd (“Truth”) a subsidiary of The Marketing Group plc, (“TMG” or the “Company”), which trades as RYVL, announces the launch of an Initial Coin Offering (“ICO”) for Truth Data Cloud, its blockchain-based data marketplace which will let consumers be rewarded for sharing their own private internet browsing data. The Truth ICO will run until 15 November 2018 or when the maximum targeted amount has been raised and it is targeted to raise between US$5 million and US$50 million. Initial commitments of over US$1 million have already been received. Truth Data Cloud is a blockchain-

REPURCHASED SHARES IN KARO PHARMA DURING WEEK 28 2018

During the period 9 July 2018 to 13 July 2018, Karo Pharma AB (publ) (LEI code 213800G54Z51LOPGTA79) has repurchased in total 387,062 own shares (ISIN: SE00007464888). The repurchases form part of the SEK 86.3 million share repurchase programme that Karo Pharma announced on 18 June 2018. The share repurchase programme, which runs between 18 June 2018 and 31 August 2018, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (”MAR”) and the Commission Delegated Regulation (EU) No 2016/1052.During the period 9 July 2018 – 13 July 2018, shares in Karo Pharma have

Orkla ASA: Orkla initiates share buyback program

Orkla ASA (''Orkla'') has decided to initiate a share buyback program for up to 10 million shares in the market. The buyback program will be conducted in accordance with the authorization provided by the annual general meeting to the board of directors on 12 April 2018. The buyback will be executed according to the market price on the Oslo Stock Exchange. The program will be initiated today and terminated on 31 August 2018 at the latest. The shares purchased under this program will be used for amortization purposes. Orkla ASA Oslo, 16 July 2018 Ref.: Vice President Group Treasury Jan

MSAB receives significant Q3 order from the French Gendarmerie Nationale

As a result of MSAB's market presence and continued development of state of the art mobile forensic solutions, the company has received an order of approximately 12 MSEK from the French Gendarmerie Nationale with delivery scheduled in the third quarter. The order is for the MSAB extraction solution, XRY, for frontline usage. The solution is user-friendly and designed for quick and easy extraction of information from digital devices, without requiring special expertise.  "We have a strong position in Europe already but we still see many opportunities for additional growth. MSABs biggest

In line with expectations after a late start to the season

Inwido’s President and CEO, Håkan Jeppsson, comments on the second quarter of 2018:“Following the late start of the season, we delivered a second quarter largely in line with expectations, confirming that our strategy of broadening the operations and increasing e‑commerce is working.”  “Sales increased by 3% to SEK 1,729 million, organically down 2%, and the operating EBITA margin was 10.6% (11.5). The lower profitability can primarily be attributed to effects of the year’s cold and late winter and weaker development in our Swedish operations. Order bookings increased 5% compared with

Interim report January-June 2018

This information is such that Inwido AB (publ) is obliged to publish in accordance with the EU market abuse regulation. The information was submitted by the below contact persons for publication on 16 July 2018 at 7:45 a.m. CET. In line with expectations after a late start to the season April – June 2018 · Net sales rose to SEK 1,729 million (1,673), representing an increase of 3 percent. Organic growth was negative 2 percent · EBITA amounted to SEK 184 million (192) after items affecting comparability of SEK 0 million (negative 1), and the EBITA margin was 10.6 percent (11.5)

Share buy-backs in Telia Company during week 28 2018

During the period July 9, 2018, until July 13, 2018, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 2 400 000 own shares (ISIN: SE0000667925). The share buy-backs form part of the SEK 5 billion share buy-back programme that Telia Company announced on April 20, 2018. The share buy-back programme, which runs between April 23, 2018, and March 22, 2019, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (”MAR”) and the Commission Delegated Regulation (EU) No 2016/1052 (the “Safe Harbour Regulation”).During the period July 9,

There are no items matching the current filter
There are no more items matching the current filter
Back to top